RecruitingPhase 2NCT05574387

Metformin as Added on Therapy in Patients With Ulcerative Colitis

Metformin, The Biguanide Derivative, as Adjuvant Therapy in Patients With Ulcerative Colitis Treated With Mesalamine

Sponsor

Tanta University

Enrollment

46 participants

Start Date

Jan 20, 2023

Study Type

INTERVENTIONAL

Conditions

Inflammatory Bowel Diseases

Summary

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that is marked by increased intestinal motility and bloody diarrhea. The clinical value of existing therapeutic strategies of UC, including glucocorticoids, anti-tumor necrosis factor α (TNF-α), mesalamine, and thiopurines is still limited. Therefore, the discovery of new therapeutic approaches is essential to improve the effectiveness of the treatment.Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a conserved fuel-sensing enzyme that plays an important role in the regulation of cellular metabolism where it increases glucose and fatty acids uptake and activates the oxidation process to improve the cellular energy utilization

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether metformin — a medication commonly used for diabetes — can help treat ulcerative colitis (UC), an inflammatory bowel disease, when added to existing treatment. Researchers believe metformin's anti-inflammatory properties may benefit people with UC. **You may be eligible if...** - You are 18 or older - You have been diagnosed with mild to moderate ulcerative colitis confirmed by colonoscopy - You have a negative pregnancy test and are using effective contraception (if applicable) **You may NOT be eligible if...** - You are breastfeeding - You have significant liver or kidney problems - You have diabetes - You have colorectal cancer - You have severe ulcerative colitis - You are currently taking steroids or immunosuppressive medications Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMetformin

Metformin is an antidiabetic biguanide drug that acts by promoting glucose uptake and utilization in the liver.Recent studies proved that metformin could reduce colonic inflammation by AMPK-mediated inhibition of p38 mitogen-activated protein kinase (MAPK)